I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Metabolic syndrome (syndrome X, insulin resistance syndrome) consists of constellation of metabolic abnormalities which include central obesity, hyperglycemia plus insulin resistance, high triglycerides plus low HDL cholesterol, and hypertension (the deadly quartet).\[[@ref1]\] Third National health and Nutrition Examination Surveys (NHANES III) revealed the age adjusted prevalence of metabolic syndrome to be 34% in men and 35% in women in the Unites States.\[[@ref2]\] In a multiethnic study in Singapore, 28.8% of Indians, 24.2% of Malaysians, and 14.8% of Chinese had metabolic syndrome.\[[@ref3]\] With rapid industrialization and urbanization, the prevalence of metabolic syndrome has increased dramatically. By NCEP (National Cholesterol Education Programme) criterion, 41.1% of Asian Indians were suffering from metabolic syndrome\[[@ref4]\] whereas the prevalence of metabolic syndrome was 11.2% in Chennai urban population.\[[@ref5]\]

Obesity, a key component of metabolic syndrome, occurs due to increased energy intake, decreased energy expenditure, or a combination of both, thus leading to positive energy balance. Thyroid hormones up-regulate metabolic pathways relevant to resting energy expenditure, hence, obesity and thyroid functions are often correlated. On one hand, obesity *per se* causes alterations in thyroid hormones, i.e. increased thyroid hormone levels,\[[@ref6]\] increased TSH with no effect on T~3~ and T~4~,\[[@ref7]--[@ref9]\] or increase in TSH and T~3~ with no effect on T~4~\[[@ref10]--[@ref12]\]; on the other hand, subclinical hypothyroidism as a result of slow metabolism can lead to the obesity.\[[@ref13]\] It is still not clear whether these alterations in thyroid hormones are a cause or an effect of obesity (metabolic syndrome).

One fact is clear that clinicians often interpret increased TSH levels with normal thyroid hormone levels in obese persons as an evidence of subclinical hypothyroidism and prescribe thyroxine replacement therapy to reinforce the euthyroid status which already exists. It has also been noted that the unnecessary use of thyroxine replacement can lead to its toxicity. The mechanism of normal levels of T~3~, T~4~ with increased TSH in metabolic syndrome is not defined, but it has been hypothesized that metabolic syndrome is associated with insulin resistance due to the defect in postreceptor signal transduction in target tissue, a similar mechanism of thyroid receptor resistance might be operating in these obese persons.\[[@ref7]\] Thus, in order to explore the possibility of thyroid receptor resistance to TSH, this study was designed to find alterations in metabolic syndrome (obese insulin resistant individuals, defined by the HOMA model).\[[@ref14]\]

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

Study design {#sec2-1}
------------

The study was carried out in 40 patients with metabolic syndrome fulfilling three or more NCEP ATP III criteria (namely waist circumference \>102 cm in men and \>88 cm in women, blood pressure ≥130/≥85 mmHg, triglycerides ≥150 mg/dl, HDL cholesterol \<40 mg/dl in males and \<50 mg/dl in females, and fasting glucose ≥110 mg/ dl). Twenty nonobese persons were taken as the control (group II). We excluded the subjects with a history of thyroid diseases or radioiodine treatment, antithyroid treatment, thyroid autoantibody positive subjects, and pregnant women. All patients gave a written consent, and the institutional review board at the University of Health Sciences approved the study protocol.

Anthropometric parameters, thyroid function tests, blood glucose, and serum insulin levels {#sec2-2}
------------------------------------------------------------------------------------------

Body weight (kg) and height (m) were measured using standardized techniques and equipment. The BMI was calculated as weight divided by squared height (kg/m^2^). The waist circumference was measured with a paper tape horizontally at the level of umbilicus in the standing position. The hip circumference was measured at the level of greater trochanter. A waist-to-hip ratio was calculated as waist circumference divided by hip circumference. Blood pressure was measured from the left arm in the sitting position with apparatus at the level of heart. Venous blood samples were taken after 12 h of fasting, separated and frozen at -8°C until analysis. The serum levels of TSH (reference range, 0.17--4.05 μIU/ml), T~3~ (reference range, 70--200 ng/dl), and T~4~ (reference range, 5.5--13.5 μg/dl) were measured as indicators of thyroid function using I-125 gamma counter (IC 4702A, Electronics Corporation of India, India) with radioimmunoassay kits (IRMAK 9, RIAK 4/4A, and RIAK 5/5A, respectively; Board of Radiation and Isotope Technology, Navi Mumbai, India). The serum insulin levels (reference range, 1--30 mU/l) were also measured using a radioimmunoassay kit (RIAK 1, Board of Radiation and Isotope Technology, Navi Mumbai, India). Blood sugar levels (reference range, 60--100 mg/dl) were estimated by the glucose oxidase-peroxidase (GOD-POD) method using the glucose analyzer (Techno 168, Logotech India Pvt. Ltd., India). Fasting serum concentrations of triglycerides and HDL were measured using commercially available kits.

Homeostasis model assessment for insulin resistance {#sec2-3}
---------------------------------------------------

To define the insulin resistance, homeostasis model assessment for insulin resistance (HOMA IR) was calculated by the following formula\[[@ref14]\]:
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Statistical analysis {#sec2-4}
--------------------

The data were analyzed using SPSS software (version 12.0 for windows, SPSS, Inc., Chicago, IL). Statistical significance was calculated by the Student '*t*'-test. An unpaired '*t*'-test was used for intergroup comparison. The *P* value was calculated for statistical significance. The *P* value \<0.05 was taken as significant. Data were expressed as mean±SD.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

General characteristics of the subjects in both groups {#sec2-5}
------------------------------------------------------

The mean age of the patients (group I) and the controls (group II) was 38.24±9.17 years and 34.16±11.61 years, respectively. A female-to-male ratio (sex ratio) was 3:2 in both the groups. The mean waist circumference was 99.10±8.88 cm in patients and 74.85±9.44 cm in controls (*P* \<0.0001). The mean systolic and diastolic blood pressure were 133.3±13.8 mmHg and 87.5±9.8 mmHg, respectively, in group I patients whereas the mean systolic and diastolic blood pressure were 111.6±11.6 mmHg and 74.2±9.64 mmHg, respectively, in group II individuals and the difference was statistically significant. The mean blood sugar levels were 114.4±9.34 mg/dl in group I individuals as compared to 79.65±11.28 mg/dl in controls (*P* \<0.0001). Similarly, there was a significant difference in triglyceride levels (162.79±52.44 vs. 108.8±36.57 mg/dl; *P* = 0.0002) and HDL cholesterol levels (39.24±5.03 vs. 48.48±4.9 mg/ dl; *P* \<0.0001) in both groups \[[Table 1](#T1){ref-type="table"}\].

###### 

Individuals with metabolic syndrome (group I) and controls (group II)
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Homeostasis model assessment for insulin resistance {#sec2-6}
---------------------------------------------------

HOMA IR (homeostasis model assessment for insulin resistance) was calculated in both groups. The standardized value of HOMA IR (mean+2SD = 5.7) obtained in group II was taken as a reference value to define the insulin resistance. The mean HOMA IR was 7.78±1.58 in group I and 3.73±0.98 in group II individuals, and the difference was significant (*P* \<0.0001).

Comparison of thyroid functions in obese (group I) and control (group II) subjects {#sec2-7}
----------------------------------------------------------------------------------

Thyroid function tests were done in both groups. The mean T~3~ levels were comparable in both the groups (117.82±27.56 vs. 124.75+14.55 ng/dl; *P* = 0.31). Similarly the difference in mean T~4~ levels was also nonsignificant in both the groups (7.77±1.37 vs. 7.31±1.20 μg/dl; *P* = 0.23). Mean TSH levels in group I individuals were higher as compared to group II (5.68±1.90 μIU/ml *vs*. 2.19±0.94 μIU/ml) and the rise was statistically significant (*P* \<0.0001) as shown in [Table 2](#T2){ref-type="table"}.

###### 

HOMA IR and thyroid function tests in both groups
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D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Metabolic syndrome can be associated with endocrinal and nonendocrinal disorders and has widespread consequences. Alterations in thyroid functions, though well known yet, are not recognized clinically and there is inconsistency in the thyroid functions in metabolic syndrome. The rise in TSH with normal T~3~ and T~4~ is mostly reported,\[[@ref7]--[@ref9]\] but the rise in TSH with alteration in T~3~ without any effect on T~4~\[[@ref10]--[@ref12]\] or increased thyroid hormone levels\[[@ref6]\] also have been described in obesity. These disturbances in the thyroid function do not have any physiological basis, because it cannot be explained by the feedback mechanism. By this study, we tried to explore the possibility of thyroid receptor résistance akin to insulin resistance in metabolic syndrome and made interesting observations.

Forty obese individuals fulfilling the NCEP ATP III criteria were taken as cases and 20 healthy individuals served as controls. Patients with prior history of thyroid disease, history of antithyroid treatment, with positive antithyroid antibody and pregnancy were excluded. All the subjects were subjected to the thyroid hormone assay. The persons in both groups were made comparable with regards to age and sex but had significant difference with regards to components of metabolic syndrome as displayed in [Table 1](#T1){ref-type="table"}.

Keeping in mind that metabolic syndrome is associated with insulin resistance with hyperinsulinemia as a metabolic consequence\[[@ref15]\]; it is possible that these patients might have thyroid receptor resistance resulting in persistent elevated TSH levels. The stimulus for increased TSH could be accounted by the elaboration of certain hormones namely leptin, adiponectin from the fatty tissue which cross the blood--brain barrier and stimulate the hypothalamic pituitary axis.\[[@ref16][@ref17]\] To explore the thyroid receptor resistance, we took the help of HOMA IR to define insulin resistance. The cut off limit of HOMA IR was derived from the individuals of group II as 5.7 (mean+2SD). All patients in group I were insulin resistant as per the HOMA IR model.

The mean levels of T~3~ (117.82±27.56ng/dl) and T~4~ (7.77±1.37μg/dl) in group I and mean T3 (124.75±14.55 ng/dl) and T~4~ levels (7.31±1.20 μg/dl) in group II were comparable; however, the mean levels of TSH in group I (5.68 ± 1.90 μIU/ml) were significantly higher than in group II (2.19 ± 0.94 μIU/ml). The raised TSH levels with normal T~3~ and T~4~ could not be explained on the basis of the feedback system. These findings also do not explain the state of subclinical hypothyroidism as all these patients were antithyroid peroxidase antibody negative.

Our finding suggest that insulin-resistant obese persons had higher TSH levels as compared to normal individuals but T~3~ and T~4~ levels were comparable in both groups. Raised TSH thus could be a metabolic consequence of metabolic syndrome rather than a state of subclinical hypothyroidism.

From our findings, it can be hypothesized that raised TSH levels in obese persons with insulin resistance (metabolic syndrome) could be due to association of thyroid receptor resistance to TSH similar to insulin resistance. The normal levels of T~3~ and T~4~ support this hypothesis. The stimulus for rise in TSH could also be due to hormones secreted by adipose tissue. Since we did not estimate these hormones (leptin, resistin, adiponectin, etc.) in our study, thus are not able to comment on the effect of these hormones on thyroid function tests.

To conclude, it is suggested that these findings are preliminary and require evaluation on a large scale with inclusion of various hormones elaborated by adipose tissue.

C[ONCLUSION]{.smallcaps} {#sec1-5}
========================

To conclude, it is suggested that these findings are preliminary and require evaluation on a large scale with inclusion of various hormones elaborated by adipose tissue.
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